Introduction {#S1}
============

Henoch-Schönlein purpura (HSP), an immune-mediated disorder, preferentially affecting children. It is characterized by petechiae, arthralgia, and gastrointestinal manifestations, including abdominal pain, gastrointestinal bleeding, intussusception, and perforation.^[@R1]^ Histological examination reveals systemic necrotizing vasculitis of small vessels. Protein-losing enteropathy (PLE) is a rare complication of HSP, with only six previous pediatric reports.^[@R2]--[@R7]^

Here, two pediatric HSP patients who developed PLE are reported, along with a literature review.

Case Report {#S2}
===========

Case \#1
--------

A 4-year-old boy was hospitalized with colicky abdominal pain. There was no recent drug exposure or immunization, and his family history was unremarkable.

Four days before admission, he had low grade fever and vomiting, and was treated by a family physician. Because of continuing abdominal pain, he was admitted to our hospital with suspected acute gastroenteritis. On admission, he had vomiting and abdominal pain. He was 113 cm tall (±1.63 SD) and weighed 18.4 kg (±0.3 SD). His temperature was 37.4°C, his pulse was 98/min, and his general condition was poor, with abdominal tenderness but no guarding, and no purpura.

Admission laboratory tests showed leukocytosis (19×10^9^/L, 76.6% neutrophils), decreased serum total protein (3.0 g/dL), albumin (1.8 g/dL,) and plasma factor XIII activity (17%), and increased fibrinogen (204 mg/dL), thrombin-antithrombin III complex (TAT) (10.1 ng/mL), fibrin/fibrinogen degradation products (FDP) (22.4 ng/mL), and D-dimer (24.1 µg/mL). The immunologic profile was normal except for low IgG (386 mg/dL). The Guaiac test for fecal occult blood was positive.

On the day after admission, he developed bloody stool and purpura on the lower extremities and scrotum. With a diagnosis of HSP with gastrointestinal involvement, prednisolone (1.5 mg/kg/day), dalteparin (75 U/kg/day), and urinastatin (2,500 U/kg/dose) were started. There was marked edema of eyelids and upper and lower extremities. The patient\'s serum albumin decreased to 1.8 g/dL, necessitating albumin infusion. His plasma factor XIII activity also decreased to 17%, necessitating human antihemophilic factor XIII fraction. Plasma factor XIII and serum albumin levels normalized by the 10th day. He was discharged on the 35th day.

On plain abdominal CT ([Figure 1](#F1){ref-type="fig"}), diffuse wall thickening in the small bowel and colon and a small amount of ascites were noted.

Figure 1On abdominal computerized tomography, diffuse wall thickening is noted in the small bowel and colon. A small amount of ascites is seen.

Tc 99m-human serum albumin (HSA) scintigraphy showed activity in the stomach and duodenum 60 min after injection, suggesting PLE. During the course, no urine abnormalities were detected. His transient hypoproteinemia was likely due to PLE, because it normalized as his abdominal symptoms improved.

Case \#2
--------

A 5-year-old boy was admitted with abdominal pain, vomiting, bloody stool, and a rash on his legs. He had no recent drug exposure or immunization, and his family history was unremarkable. Seven days before admission, purpura developed on his nose and around his mouth, followed by abdominal pain and purpura on the upper and lower extremities, involving his buttocks one day later. HSP was diagnosed.

Because of continuing abdominal pain, he was admitted to our hospital. On admission, he had vomiting, abdominal pain, and bloody stool. He was 121.8 cm tall (±1.9 SD) and weighed 22.8 kg (±0.8 SD). His temperature was 36.9°C, pulse was 90/min, and blood pressure was 90/58 mmHg. His general condition was poor, with abdominal tenderness but no guarding, and purpura on the earlobes, lower extremities, and scrotum.

Admission laboratory tests showed leukocytosis (19.3×10^9^/L, 88.0% neutrophils), elevated C-reactive protein (7.06 mg/dL), decreased serum total protein (6.1 g/dL), albumin (3.1 g/dL), and plasma factor XIII activity (46%), and increased TAT (20.8 ng/mL), FDP (18.2 ng/mL), and D-dimer (18.4 µg/mL). The Guaiac test for fecal occult blood was positive. The anti-streptolysin-O (ASO) titer was 900 IU/mL, and the anti-streptokinase (ASK) titer was 1,280 dil. A throat culture was positive for α-hemolytic Streptococcus. Streptococcal infection was diagnosed, and ABPC (100 mg/kg/day) was given. With a diagnosis of HSP with gastrointestinal involvement, prednisolone (1.5 mg/kg/day), dalteparin (75 U/kg/day), and urinastatin (2500 U/kg/dose) were started. Plasma factor XIII and serum albumin levels normalized by the 10^th^ day as his abdominal symptoms improved.

On abdominal CT, diffuse wall thickening was noted in the stomach. Tc-99m-HAS scintigraphy showed activity in the stomach 60 min after injection, suggesting PLE. During the course, no urine abnormalities were detected.

Discussion {#S3}
==========

Gastrointestinal manifestations of PLE rarely occur with HSP. PLE is a rare condition characterized by gastrointestinal loss of serum protein resulting in hypoproteinemia, which can cause edema, ascites, pleural and pericardial effusions, and malnutrition. Increased capillary permeability or submucosal hemorrhage and ulceration by vasculitis might cause the protein loss.^[@R2]^ PLE is rare in HSP, with only eight reported pediatric cases, including our two cases^[@R2]--[@R7]^ ([Table 1](#T1){ref-type="table"}). These patients (7 boys, 1 girl; age range, 4 to 14 years) all had abdominal pain; four had several unusual complications (case \#\# 2, 3, 4, 6). Case \#4^[@R5]^ had abdominal pain, but the stool was Guaiac-negative. Moderate hypoproteinemia (4.9 g/dL) and hypoalbuminemia (2.5 g/dL) without proteinuria were detected during the acute phase; the serum protein levels increased gradually on steroid therapy, but severe neurological involvement resulted from cerebral vasculitis. Case \#6,^[@R7]^ a 4-year-old boy, had severe esophagitis and multiple ulcers in the descending duodenum presenting as PLE. However, our cases had PLE without other complications.

Table 1Pediatric Henoch-Schönlein purpura patients with protein-losing enteropathy.CaseAge (years)/sexIntestinal bleedingTreatmentOther symptomsReferences114/M(+)PSLAbdominal pain joint pain, peripheral pitting edemaReif *et al.*, 1991^[@R2]^26/M(+)PSLAbdominal pain, urolithiasis, hydrops of the gallbladder, pancreatic involvement, scrotal hemorrhage, testicular swelling, pyeloureteritisBosio *et al.*, 1993^[@R3]^310/M(+)PSL, mPSL pulseAbdominal pain, hydronephrosis, gallbladder abnormalities, purpura nephritisKano *et al.*, 1998^[@R4]^412/M(−)PSLabdominal pain, cerebral vasculitis, testicular swellingBakkalo lu *et al.*, 2000^[@R5]^58/F(?)PSL, F XIIIAbdominal painKaneko *et al.*, 2004^[@R6]^64/M(+)PSLAbdominal painDalgiç *et al.*, 2005^[@R7]^74/M(+)PSL, F XIII, dalteparin, urinastatinAbdominal painPresent report85/M(+)PSL, dalteparin, urinastatinAbdominal painPresent report[^3]

Previously, the detection and quantification of gastrointestinal protein loss primarily involved measurement of fecal excretion of albumin labeled with I-125 or Cr-51 after intravenous tracer injection. However, stool collection is difficult, with false-positive results if the stool specimen is contaminated with urine. Subsequently, measurement of fecal excretion of α1-antitrypsin was used to detect PLE.^[@R8]^ This serum enzyme, with the same molecular weight as albumin, resists proteolysis and is not degraded when it leaks into the intestinal lumen. However, this is difficult because stool must be collected. Recently, Tc-99m HAS scintigraphy has been used to diagnose PLE by documenting protein loss in the gut, which is also useful for monitoring response to treatment.^[@R9]--[@R10]^ Our two patients were diagnosed as having PLE because of hypoalbuminemia without nephrosis or liver dysfunction, as well as abnormal leakage of the radiotracer into the gut on Tc-99m HSA scintigraphy. Tc-99m HAS scintigraphy offers a rapid, safe, and convenient way to screen and localize PLE. In HSP patients, Tc-99m HSA scintigraphy is useful for detecting PLE.
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